<DOC>
	<DOC>NCT00180167</DOC>
	<brief_summary>Single Arm-Studies suggest improved remission and survival rates for a Protocol with Mitoxantron 10mg/m2 for 3 days combined with AraC 1g/m2 bid on days 1+3+5+7 compared to a conventional DA 7+3 protocol (45mg/m2 Daunorubicin).</brief_summary>
	<brief_title>Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC</brief_title>
	<detailed_description>Randomized comparison of the two protocols.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Diagnosis of AML age &gt;60 no previous Chemo for AML informed consent Karnofsky &gt;70 AML M3 uncontrolled Sepsis uncontrolled HYpertension respiratory failure heartfailure NYHA IV, recent myocardial infarction severe organ dysfunction of liver, kidneys, HIV infection or active Hepatitis B,C</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>elderly</keyword>
</DOC>